The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future
Open accessAbstract
The current problems with increasing bacterial resistance to antibacterial therapies, resulting in a growing frequency of incurable bacterial infections, necessitates the acceleration of studies on antibacterials of a new generation that could offer an alternative to antibiotics or support their action. Bacteriophages (phages) can kill antibiotic-sensitive as well as antibiotic-resistant bacteria, and thus are a major subject of such studies. Their efficacy in curing bacterial infections has been demonstrated in in vivo experiments and in the clinic. Unlike antibiotics, phages have a narrow range of specificity, which makes them safe for commensal microbiota. However, targeting even only the most clinically relevant strains of pathogenic bacteria requires large collections of well characterized phages, whose specificity would cover all such strains. The environment is a rich source of diverse phages, but due to their complex relationships with bacteria and safety concerns, only some naturally occurring phages can be considered for therapeutic applications. Still, their number and diversity make a detailed characterization of all potentially promising phages virtually impossible. Moreover, no single phage combines all the features required of an ideal therapeutic agent. Additionally, the rapid acquisition of phage resistance by bacteria may make phages already approved for therapy ineffective and turn the search for environmental phages of better efficacy and new specificity into an endless race. An alternative strategy for acquiring phages with desired properties in a short time with minimal cost regarding their acquisition, characterization, and approval for therapy could be based on targeted genome modifications of phage isolates with known properties. The first example demonstrating the potential of this strategy in curing bacterial diseases resistant to traditional therapy is the recent successful treatment of a progressing disseminated Mycobacterium abscessus infection in a teenage patient with the use of an engineered phage. In this review, we briefly present current methods of phage genetic engineering, highlighting their advantages and disadvantages, and provide examples of genetically engineered phages with a modified host range, improved safety or antibacterial activity, and proven therapeutic efficacy. We also summarize novel uses of engineered phages not only for killing pathogenic bacteria, but also for in situ modification of human microbiota to attenuate symptoms of certain bacterial diseases and metabolic, immune, or mental disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current understanding of the human microbiome
Gilbert, J. A., Blaser, M. J., Caporaso, J. G., Jansson, J. K., Lynch, S. V., & Knight, R. (2018) · Nature Medicine · doi:10.1038/nm.4517 · Cited by 2,609
The central nervous system and the gut microbiome
Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016) · Cell · doi:10.1016/j.cell.2016.10.027 · Cited by 1,513
Diversity, classification and evolution of CRISPR-Cas systems
Koonin, E. V., Makarova, K. S., & Zhang, F. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.05.008 · Cited by 1,423 · cited 1×
“A customized CRISPR-Cas system from Streptococcus pyogenes, which requires only one protein (Cas9) for crRNA processing and target recognition and cleavage [214], has successfully been used to introduce point mutations, deletions, or insertions to the genomes of obligatorily lytic phages infecting Gram-negative as wel…”
BackgroundSchooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00954-17 · Cited by 1,254
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials
Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A., & Marraffini, L. A. (2014) · Nature Biotechnology · doi:10.1038/nbt.3043 · Cited by 986
Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier
Martens, E. C., Neumann, M., & Desai, M. S. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0036-x · Cited by 711
Formulation, stabilisation and encapsulation of bacteriophage for phage therapy
Malik, D. J., Sokolov, I. J., Vinner, G. K., Mancuso, F., Cinquerrui, S., Vladisavljevic, G. T., Clokie, M. R. J., Garton, N. J., Stapley, A. G. F., & Kirpichnikova, A. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.05.014 · Cited by 594
Alterations in Enteric Virome Are Associated With Colorectal Cancer and Survival Outcomes
Nakatsu, G., Zhou, H., Wu, W. K. K., Wong, S. H., Coker, O. O., Dai, Z., Li, X., Szeto, C.-H., Sugimura, N., Lam, T. Y.-T., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.018 · Cited by 386
Introduction of foreign DNA into mycobacteria using a shuttle phasmid
Jacobs, W. R., Tuckman, M., & Bloom, B. R. (1987) · Nature · doi:10.1038/327532a0 · Cited by 314 · cited 1×
“coli as a plasmid and propagate in Mycobacterium as a phage, was constructed by the insertion of a cosmid into a non-essential ~ 50-kbp region of mycobacteriophage DNA [176].”
BackgroundLoureiro, A., & da Silva, G. J. (2019) · Antibiotics · doi:10.3390/antibiotics8010018 · Cited by 129
Cited by
Phage therapy: From biological mechanisms to future directions
Strathdee, S. A., Hatfull, G. F., Mutalik, V. K., & Schooley, R. T. (2023) · Cell · doi:10.1016/j.cell.2022.11.017 · Cited by 817
Genetically Engineered Microorganisms and Their Impact on Human Health
Mahdizade Ari, M., Dadgar, L., Elahi, Z., Ghanavati, R., & Taheri, B. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/6638269 · Cited by 67
The power of phages: revolutionizing cancer treatment
Islam, M. S., Fan, J., & Pan, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1290296 · Cited by 50
Bacteriophage-Mediated Cancer Gene Therapy
Petrov, G., Dymova, M., & Richter, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214245 · Cited by 38
“Due to the growing antibiotics resistance of bacteria, phage therapy for infectious diseases is currently experiencing a renaissance [29].”
BackgroundMafe, A. N., & Büsselberg, D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070820 · Cited by 18
Metadata
- Authors
- Łobocka, M., Dąbrowska, K., & Górski, A.
- Venue
- BioDrugs
- Published
- 2021-04-21
- Volume
- 35
- Issue
- 3
- Pages
- 255-280
- ISSN
- 1172-7039 (ISSN-L)
- 1173-8804
- 1179-190X
- OpenAlex
- W3152554333
- Cited by
- 175
- References
- 10
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future. https://app.cochat.ai/papers/10.1007/s40259-021-00480-z
- The paper
- Łobocka, M., Dąbrowska, K., & Górski, A. (2021). Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future. BioDrugs. https://doi.org/10.1007/s40259-021-00480-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.